Biotechnology company Vergent Bioscience has revealed that VGT-309, its investigational tumor-targeted fluorescent imaging agent, is able to help surgeons see lung tumors in real time during surgical procedures.
NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.